Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric citrate - Akebia Therapeutics

Drug Profile

Ferric citrate - Akebia Therapeutics

Alternative Names: Auryxia; Ferric citrate dihydrate; Fexeric; JTT-751; KRX-0502; Nephoxil; Riona; Tetraferric tricitrate decahydrate; Zerenex

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panacor Bioscience; Panion & BF Biotech
  • Developer Akebia Therapeutics; Japan Tobacco; Panion & BF Biotech; Torii Pharmaceutical
  • Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids
  • Mechanism of Action Iron replacements; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia; Iron deficiency anaemia

Most Recent Events

  • 25 Oct 2019 Akebia Therapeutics initiates enrolment in the ASTRIO trial for Iron deficiency anaemia
  • 06 Aug 2019 Akebia Therapeutics and its licensor Panion & BF Biotech entered into a Settlement and License Agreement with Par Pharmaceutical to market a generic version of ferric citrate tablets in USA
  • 09 Jul 2019 Japan Tobacco and Torii Pharmaceutical announces intention to submit regulatory application to the Ministry of Health, Labour and Welfare for Iron deficiency anaemia in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top